Approximately 250 international experts came together at a Kidney and Liver Transplant meeting to discuss the challenges associated with the increasing organ gap. The meeting brought forth the impact of recent advances in the management of kidney and liver transplant patients on the prolongation of the patient and transplanted organ survival.
• Kidney and liver failure is caused by sudden complications like injury or damage from medicine or long term chronic diseases like kidney or liver disease, diabetes, high blood pressure and heart failure
• According to American Diabetes Association prevalence of type 1 diabetes is 2.8% among expatriates and 2.3% among natives (age-group 0–20 years) in Kuwait. Asian expatriates (age-group 30–60 years) exhibit higher prevalence of type 2 diabetes at 33.25% than natives at 25.4%. Prevalence of hypertension is 37% amongst Asians and 28% amongst natives of Kuwait.
• Local experts joined hands with international experts to identify how best immunosuppression therapy can be used to improve the long-term survival rates of post-transplant patients
Leading global surgeons, nephrologists and hepatologists from Asia, Australia, Turkey, Middle-East and Africa, gathered for a two-day scientific summit on Liver and Kidney Transplant. Chaired by Dr. Steve Chadban- Director of Kidney Transplantation at Royal Prince Alfred Hospital, Australia and Dr. Gary Levy- Director of Transplantation Institute at University of Toronto, Canada; the summit aimed to find solutions to the unmet challenges of kidney and liver transplant to improve patient long term outcomes in the region.
Kidney and liver transplant is the ultimate hope for patients with acute kidney and liver failure. According to Global Observatory on Donation & Transplantation, supported by WHO, around 77818 kidney transplants and 23986 liver transplants were performed across 91 countries in 2012. Currently, 112,000 solid organ transplants take place each year, but the requirement is far more than the availability.
This is resulting in growing transplant wait lists and increasing number of people dying while waiting.2 It is often noticed that in spite of successful transplant operation and lowered post-surgery complications, long-term patient and transplanted organ survival is needed to be improved.
“There is an increasing gap worldwide between the number of organs available for donation and the number of patients who need a transplant, and unfortunately many patients die while on the waiting list. There is a need for policies that can enhance awareness of organ donation to increase the number of organs available and for techniques to allow organs presently not being used to be repaired and used as well as approaches to keeping the transplanted organ functioning for as long as possible and to improve long term survival of transplanted patients”, said Professor Gary Levy
“Success in transplantation goes beyond the surgery. The choice and careful management of the most appropriate immunosuppressive treatment for the individual patient is crucial to achieve the balance of preventing graft rejection and ensuring long-term graft function and patient survival”, said Professor Steve Chadban.
Through series of lectures, workshops, panel discussions and interactive sessions the experts debated the latest advances in Liver and Kidney transplantation.
“Scientific forums like this meeting offer a great opportunity for experts in transplantation from different countries to meet to review data and define novel approaches to improve the care of transplant patients. Although short-term results of transplantation are excellent, toxicity associated with the use of immunosuppressive agents limits longer term outcomes and thus new approaches must be considered”, said Professor Gary Levy.
Novartis has more than 30 years of history in transplantation and is deeply committed to develop new treatments that can improve the lives of transplant recipients.